`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owner.
`__________________
`
`Case No. IPR2019-00685
`U.S. Patent No. 9,211,253
`__________________
`
`DECLARATION OF ANA C. REYES IN SUPPORT OF MOTION FOR
`PRO HAC VICE ADMISSION PURSUANT TO 37 C.F.R. § 42.10(c)
`
`Opiant Exhibit 2038
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00685
`Page 1
`
`
`
`I, Ana C. Reyes, am more than twenty-one years of age, am competent to
`
`present this declaration, have personal knowledge of the facts set forth herein, and
`
`hereby declare as follows:
`
`1.
`
`This declaration is given in support of Patent Owner Adapt Pharma
`
`Operations Limited’s Motion for Pro Hac Vice Admission of Ana C. Reyes.
`
`2.
`
`I am a partner at Williams & Connolly LLP, 725 12th St., NW,
`
`Washington, DC 20005. I have more than eighteen years of litigation experience.
`
`3.
`
`I am a member in good standing of the bars of New York, the District
`
`of Columbia, and Kentucky.
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`6.
`
`No court or administrative body has ever imposed sanctions or
`
`contempt citations on me.
`
`7.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`8.
`
`I understand that I will be subject to the USPTO Code of Professional
`
`Responsibility set forth in 37 C.F.R. §§ 11.101 et seq. and will be subject to
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`Opiant Exhibit 2038
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00685
`Page 2
`
`
`
`9.
`
`I am concurrently seeking pro hac vice admission in the Petitioner’s
`
`inter partes challenge to U.S. Patent Nos. 9,211,253; 9,468,747; and 9,629,965.
`
`These proceedings have been designated Case Nos. IPR2019-00685, IPR2019-
`
`00688, and IPR2019-00694, respectively. I have not applied to appear pro hac
`
`vice in other proceedings before the Office in the last three (3) years.
`
`10.
`
`I am familiar with the subject matter at issue in the present
`
`proceeding. This familiarity comes from having:
`
`a.
`
`Reviewed in detail the pleadings submitted by Petitioner in this Case
`
`Nos. IPR2019-00685, IPR2019-00688, and IPR2019-00694;
`
`b.
`
`Reviewed in detail the challenged patents, U.S. Patent Nos.
`
`9,211,253; 9,468,747; and 9,629,965;
`
`c.
`
`Reviewed in detail exhibits relied upon by Petitioner, such as Exhibit
`
`1002 (Declaration of Maureen Donovan, Ph.D.) and Exhibit 1003 (Declaration of
`
`Günther Hochhaus, Ph.D.), etc.;
`
`d.
`
`Engaged in extensive strategic and substantive discussions regarding
`
`this proceeding with Jessamyn S. Berniker, who is the lead counsel for Patent
`
`Owner Adapt Pharma Operations Limited in this case;
`
`e.
`
`Engaged in the representation of Patent Owner Adapt Pharma
`
`Operations Limited in related matters in federal district courts, including the
`
`assertion of U.S. Patent Nos. 9,211,253; 9,468,747; and 9,629,965 in Adapt
`
`Opiant Exhibit 2038
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00685
`Page 3
`
`
`
`Pharma Operations Ltd., et al. v. Teva Pharmaceuticals USA, Inc., et al., Case No.
`
`2:16-cv-07721-BRM-JAD (D.N.J.) (consolidated) and Adapt Pharma Operations
`
`Ltd., et al. v. Perrigo UK FINCO Limited Partnership, Case No. 2:18-cv-15287-
`
`BRM-JAD (D.N.J.).
`
`11.
`
`I have reviewed in detail relevant case law and other legal authority
`
`related to the allegations made in the Petition.
`
`*
`
`*
`
`*
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true,
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like are punishable by fine or imprisonment, or both, under
`
`Section 1001 of Title 18, United States Code and may jeopardize the validity of
`
`any application or any patent issuing thereon.
`
`/Ana C. Reyes/
`Ana C. Reyes
`
`Opiant Exhibit 2038
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00685
`Page 4
`
`